We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Treatment of Sialic Acid Deficiency May Correct a Degenerative Muscle Disorder

By Biotechdaily staff writers
Posted on 11 Jun 2007
Researchers working on the rare degenerative muscle disease HIBM (hereditary inclusion body myopathy) have genetically engineered a line of mice to express a mutated gene that prevents synthesis of sialic acid, a critical sugar required for muscle development and kidney function.

The mutant mice carry the M712T mutation in the GNE gene, which codes for the key enzyme of sialic acid biosynthesis, uridine diphospho–N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. More...
The lack of this enzyme results in a kidney condition that causes newborn mice to die within a few days after birth. "We were surprised that the HIBM mutation had such a detrimental impact on kidney function in the transgenic mice,” said senior author Dr. Marian Huizing, an investigator at the [U.S.] National Human Genome Research Institute (Bethesda, MD, USA). "Structural elements in the kidney that are important for filtering waste from the blood in these animals were severely impaired, and we linked this to sialic acid deficiency. This outcome demonstrates the significance of the ability of the body to synthesize sialic acid for kidney development and function.”

To counter the lack of sialic acid, the investigators treated pregnant mutant mice with N-acetylmannosamine (ManNAc), a sialic acid precursor. Results published in the June 2007 issue of the Journal of Clinical Investigation revealed that sialic acid production was improved in fetuses, and although smaller than normal mice, the offspring displayed significantly improved kidney function. So far, none of the treated mice have displayed symptoms similar to HIBM.

The improvement seen with ManNAc treatment in mice has prompted the investigators to schedule a human clinical trial of ManNAc for HIBM to begin in late summer or early fall of 2007.


Related Links:
National Human Genome Research Institute

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Hematology Consumables
Bioblood Devices
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.